{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phosphate+buffered+saline+Placebo", "query": { "intervention": "Phosphate buffered saline Placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 111, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phosphate+buffered+saline+Placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T01:37:04.557Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05196919", "title": "Safety and Efficacy of XT-150 for Facet Joint Osteoarthritis Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Facet Joint Pain", "Back Pain", "Inflammation" ], "interventions": [ { "name": "XT-150", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xalud Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 75, "start_date": "2022-02-24", "completion_date": "2023-09-20", "has_results": true, "last_update_posted_date": "2025-01-15", "last_synced_at": "2026-09-25T01:37:04.557Z", "location_count": 3, "location_summary": "Napa, California • Santa Monica, California • Winston-Salem, North Carolina", "locations": [ { "city": "Napa", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05196919" }, { "nct_id": "NCT00866476", "title": "Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Shigella" ], "interventions": [ { "name": "CVD 1208S, a Shigella flexneri 2a live, oral vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 20, "start_date": "2010-01", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2021-04-29", "last_synced_at": "2026-09-25T01:37:04.557Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00866476" }, { "nct_id": "NCT03455309", "title": "Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Staphylococcus Aureus" ], "interventions": [ { "name": "NDV-3A", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "NovaDigm Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "17 Years", "maximum_age": "35 Years", "sex": "MALE", "summary": "17 Years to 35 Years · Male only" }, "enrollment_count": 382, "start_date": "2018-01-30", "completion_date": "2019-10-15", "has_results": false, "last_update_posted_date": "2020-01-29", "last_synced_at": "2026-09-25T01:37:04.557Z", "location_count": 1, "location_summary": "Fort Benning, Georgia", "locations": [ { "city": "Fort Benning", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03455309" }, { "nct_id": "NCT01110551", "title": "Tetravalent Chimeric Dengue Vaccine Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dengue" ], "interventions": [ { "name": "Placebo (SC)", "type": "DRUG" }, { "name": "Placebo (ID)", "type": "DRUG" }, { "name": "Modified Live Tetravalent Chimeric Dengue Vaccine (SC)", "type": "BIOLOGICAL" }, { "name": "Modified Live Tetravalent Chimeric Dengue Vaccine (ID)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 72, "start_date": "2010-05", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2013-02-04", "last_synced_at": "2026-09-25T01:37:04.557Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01110551" }, { "nct_id": "NCT04985760", "title": "Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant", "type": "BIOLOGICAL" }, { "name": "Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Madhu Chhanda Choudhary", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2021-09-30", "completion_date": "2026-01-16", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-09-25T01:37:04.557Z", "location_count": 2, "location_summary": "Columbus, Ohio • Pittsburgh, Pennsylvania", "locations": [ { "city": "Columbus", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04985760" }, { "nct_id": "NCT03113760", "title": "Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "NLRC4-MAS", "XIAP Deficiency" ], "interventions": [ { "name": "Tadekinig alfa", "type": "DRUG" }, { "name": "0.9% sodium chloride", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AB2 Bio Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 15, "start_date": "2017-07-21", "completion_date": "2023-11-02", "has_results": true, "last_update_posted_date": "2025-07-02", "last_synced_at": "2026-09-25T01:37:04.557Z", "location_count": 6, "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 3 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03113760" }, { "nct_id": "NCT00566345", "title": "Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Inactivated seasonal influenza vaccine (split virus, Vero cell-derived)", "type": "BIOLOGICAL" }, { "name": "Phosphate buffered saline", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Alachua Government Services, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 3670, "start_date": "2007-11", "completion_date": "2008-06", "has_results": true, "last_update_posted_date": "2023-10-17", "last_synced_at": "2026-09-25T01:37:04.557Z", "location_count": 34, "location_summary": "Tucson, Arizona • Anaheim, California • Sacramento, California + 31 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00566345" }, { "nct_id": "NCT01546142", "title": "Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate or Severe Submental Fullness" ], "interventions": [ { "name": "Deoxycholic acid injection", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kythera Biopharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 516, "start_date": "2012-03", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2015-06-15", "last_synced_at": "2026-09-25T01:37:04.557Z", "location_count": 30, "location_summary": "Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 26 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01546142" }, { "nct_id": "NCT04199169", "title": "Safety and Immunogenicity of a Nipah Virus Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nipah Virus Infection" ], "interventions": [ { "name": "HeV-sG-V", "type": "BIOLOGICAL" }, { "name": "Normal Saline Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Auro Vaccines LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 192, "start_date": "2020-02-18", "completion_date": "2022-05-06", "has_results": false, "last_update_posted_date": "2022-11-17", "last_synced_at": "2026-09-25T01:37:04.557Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04199169" }, { "nct_id": "NCT03275389", "title": "A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza, Human" ], "interventions": [ { "name": "D-SUIV cH8/1N1+AS03", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH5/1N1+AS03", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH11/1N1+AS03", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH8/1N1+AS01", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH5/1N1+AS01", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH11/1N1+AS01", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH8/1N1", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH5/1N1", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH11/1N1", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Fluarix Quadrivalent", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 470, "start_date": "2017-09-08", "completion_date": "2020-03-26", "has_results": true, "last_update_posted_date": "2021-05-07", "last_synced_at": "2026-09-25T01:37:04.557Z", "location_count": 5, "location_summary": "South Miami, Florida • Wichita, Kansas • Rochester, New York + 2 more", "locations": [ { "city": "South Miami", "state": "Florida" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Rochester", "state": "New York" }, { "city": "Austin", "state": "Texas" }, { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03275389" } ] }